ArticleJournal for immunotherapy of cancer2020

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors.

Aung Naing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.